Form 4 for EBS Emergent BioSolutions Inc.
Accepted 2026-02-10 00:00:00 ET · period of report 2026-02-06 · accession 0001196632-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-10 | 2026-02-06 | EBS | LINDAHL RICHARD S | EVP, CFO | D - Sale to Iss | $10.92 | -46.2K | 245.3K | -16% | -$504.0K | |
| 2026-02-10 | 2026-02-06 | EBS | LINDAHL RICHARD S | EVP, CFO | F - Tax | $10.92 | -5,642 | 239.7K | -2% | -$61.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-06 | D | D | 46,155 | $10.92 | 245,342 | D | — | — | (F1) Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 15,384 shares of common stock, which is less than the 61,539 shares previously reported on March 02, 2023 and June 09, 2023. |
| 2 | Common | Common Stock | 2026-02-06 | F | D | 5,642 | $10.92 | 239,700 | D | — | — | (F2) Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units |